Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. - Wikidata - wikimedia - TriplyDB

Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.

Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.

http://www.wikidata.org/entity/Q46826187

about

Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections How to manage aspergillosis in non-neutropenic intensive care unit patients Treatment and prophylaxis of invasive candidiasis Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications Fundament and Prerequisites for the Application of an Antifungal TDM Service Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus Therapeutic drug monitoring of voriconazole in Japanese patients: analysis based on clinical practice data.Antifungal prophylaxis in pediatric hematology/oncology: new choices & new data.Primary or secondary antifungal prophylaxis in patients with hematological maligancies: efficacy and damage.Voriconazole pharmacokinetics and pharmacodynamics in children.Voriconazole pharmacokinetics in liver transplant recipients.Voriconazole associated torsades de pointes in two adult patients with haematological malignancies.Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype.Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy.Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection.Population pharmacokinetic-pharmacodynamic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients.Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients.General principles of antimicrobial therapy.Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and Serum voriconazole level variability in patients with hematological malignancies receiving voriconazole therapy Evaluation of hepatotoxicity with off-label oral-treatment doses of voriconazole for invasive fungal infections Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Human tissue distribution of voriconazole.Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Impact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients.Inflammation is associated with voriconazole trough concentrations.Frequency of voriconazole resistance in vitro among Spanish clinical isolates of Candida spp. According to breakpoints established by the Antifungal Subcommittee of the European Committee on Antimicrobial Susceptibility Testing.Hepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation.Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections.Clinical Impact of Cytochrome P450 2C19 Genotype on the Treatment of Invasive Aspergillosis under Routine Therapeutic Drug Monitoring of Voriconazole in a Korean Population.Epidemiology and treatment approaches in management of invasive fungal infections Pharmacokinetics and safety of voriconazole intravenous-to-oral switch regimens in immunocompromised Japanese pediatric patients.Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy How much European prescribing physicians know about invasive fungal infections management?

P2860

Q26771180-EC03B7AE-D54F-454C-8627-765D4D1FADF3 Q26999448-6A365352-41E0-443C-BBB9-5D32ABD2FC59 Q27001567-09720AF8-3377-4B22-9243-B5D4063169EF Q27009221-CA4E86F6-6081-435A-B008-167CD1B72569 Q27025299-4DF8D61D-7A16-4F71-B675-922CDFDA787D Q28085352-08E5B50B-99E8-46A9-95AD-4B0FD2B707F5 Q28388806-CE72B98C-D214-456B-ACE1-43303F085539 Q28481341-41FC9405-EC13-4CC2-AF33-67BD6C5C410C Q30981299-8459E179-10ED-45FA-920F-52E7665516B2 Q33559503-243E1E15-2AB6-4F38-A2B9-E57AE7082EEE Q33573641-CCB7A61C-5E8C-416D-8D5A-C31C1924F69A Q33577291-E3C71C7C-7336-404C-8988-B1AA0C9B51DC Q33613685-D4F84B7D-EE22-4E92-B187-D8DB3D267E27 Q33625746-14D9C39A-9A2B-4395-8833-B6D0FBB6002C Q33684379-92AFA0C9-5FE3-4597-850D-3DC2CB3490D2 Q33798203-B6C1C147-F446-4BE5-B9CF-33CD18646A25 Q33827819-82CB20BC-17E5-424F-A843-F1CAE153A76A Q33849298-5522C41B-2501-4299-8DB4-3DEAE8CEFAAF Q33876645-D5D804ED-9BA5-4F1D-AFE0-AF0D41BB414C Q34020402-D80BCC3F-544D-4425-B14B-03BF010CE7F1 Q34045383-6ECEF64D-F017-4E1F-8139-A3D51D56758A Q34138276-D3EAE4DD-0FD0-4E5D-9D28-A416A5708D76 Q34150943-CBEE2338-402A-4D3C-BB4E-990F8BA021B7 Q34161745-E2BE08C6-0C34-4399-81A0-6E73ABE10EC5 Q34309603-C077CDA0-0364-4C86-A9CA-5534D53DA238 Q34413393-61FE5AAC-6CDA-43E7-9567-5FF3ED5B8960 Q34483712-C3D41A09-8095-4596-BAB9-79B9D9C25636 Q34505582-1975E7F7-80A7-40BF-A72D-944046569DE2 Q34529318-E36554D6-F39D-4824-B243-424446A014CD Q34532546-22EDBC2C-DB9E-459C-9A14-CDC3498AC42F Q34596313-6BEAC3B7-67E9-46AB-9C8F-892CEBC6324C Q34597394-6672744A-F35D-430B-AD36-846E824D33DC Q34737476-54132A8F-A383-4456-BD20-EB986B88DE07 Q34980027-5AAB23DD-3BD8-4AB3-98DB-07537EA208D9 Q35026481-EFCBC50E-6AAD-4A3C-B28D-9884DF62D9DA Q35086478-E16EFDB1-286F-4199-9762-B88153AC7004 Q35089772-8EC260D9-F689-4E7F-A895-CFE4487F7957 Q35105949-2E65C2AF-2738-48B1-ABC8-48EF01B1C0C4 Q35114591-BE103C63-56CA-4B96-80D4-7916865B3F2F Q35131938-6AAE335D-73F4-4AFA-AE25-402506A6174F

P2860

Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.

http://www.wikidata.org/entity/Q46826187

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Voriconazole therapeutic drug ...... efficacy and safety outcomes.

@en

Voriconazole therapeutic drug ...... efficacy and safety outcomes.

@nl

type

label

Voriconazole therapeutic drug ...... efficacy and safety outcomes.

@en

Voriconazole therapeutic drug ...... efficacy and safety outcomes.

@nl

prefLabel

Voriconazole therapeutic drug ...... efficacy and safety outcomes.

@en

Voriconazole therapeutic drug ...... efficacy and safety outcomes.

@nl

P1433

Q46826187-BEB118E6-FD37-4E2F-8059-9572694D69D8

P1476

Q46826187-E92FF082-4FA9-45C2-B9DF-439DA63C30DF

P2093

Q46826187-19434C8B-B4D8-407A-95C7-5CDC3ED76488

Q46826187-5216ED3C-0BFB-4497-89F1-D0BDFCB5E64C

Q46826187-91EEF474-D14F-43C5-88A7-577214C715B5

Q46826187-A9A233C4-CF75-4CA0-AE3C-BF8A6EA66163

P2860

Q46826187-06A732E1-CBEC-4130-8BA5-380DB9A0DDF0

Q46826187-13CBF727-ABD4-4A22-8F1E-D04B6EA04898

Q46826187-31E299EE-9E41-439A-8424-DC53E6DC137E

Q46826187-36F8C3DD-CAB6-47D9-AC5A-97DDC101227C

Q46826187-59BEE75B-3D5F-4C1E-9803-5DA199C20D63

Q46826187-5A5B4BAD-45EA-4040-BA91-224FF781B562

Q46826187-5FC23921-A39F-446E-B9D0-4B1B481E3355

Q46826187-69C2F172-EA53-4F8D-8B71-CD0491148045

Q46826187-6C91424C-69D7-45E3-9346-1029EBF7A548

Q46826187-754950C9-2DD1-42E7-89C5-44DDA33B0915

P304

Q46826187-B5684F9F-95B3-4F47-AD49-71B65AA455F2

P31

Q46826187-B984592B-86BB-4D41-A5FF-0357D95F50A9

P356

Q46826187-0975A2D2-7D5A-4CAE-BEFF-F6DCE72B3CBD

P407

Q46826187-2DAF5FA1-2680-4464-B9EC-88A7F826B380

P433

Q46826187-09C5837C-A88D-43CF-8763-918ACFD62A03

P478

Q46826187-F9DDB583-F099-45FC-8CE1-CA24F2E6FBB1

P50

Q46826187-52DBBD5D-7B85-48C5-B12F-D014D4849132

Q46826187-A6936D7F-677A-4859-B7B7-B6453FCBB1C3

P577

Q46826187-7FF87E40-51E1-4A20-B9C1-4A27624B9B27

P5875

Q46826187-13B2D275-328A-4806-8D2B-E529D043848A

P698

Q46826187-189B835A-7B84-4668-8417-17362ECE8513

P921

Q46826187-E4D7FE4D-A9D3-462D-9FAB-25F907C2C5F2

P356

P1433

Clinical Infectious Diseases

P1476

Voriconazole therapeutic drug ...... efficacy and safety outcomes.

@en

P2093

Andres Pascual

http://www.w3.org/2001/XMLSchema#string

Jacques Bille

http://www.w3.org/2001/XMLSchema#string

Oscar Marchetti

http://www.w3.org/2001/XMLSchema#string

Saskia Bolay

http://www.w3.org/2001/XMLSchema#string

P2860

Voriconazole therapeutic drug monitoring.

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial

Susceptibility of filamentous fungi to voriconazole tested by two microdilution methods

Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration.

Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

Voriconazole: a new triazole antifungal agent.

P304

201-211

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/524669

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P50

Thierry Calandra

P577

2008-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5679025

http://www.w3.org/2001/XMLSchema#string

P698

18171251

http://www.w3.org/2001/XMLSchema#string

P921